Frequency of rebound pain and related factors in a multimodal regimen including systemic dexamethasone and dexmedetomidine.

IF 1 Die Anaesthesiologie Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI:10.1007/s00101-025-01502-z
Funda Atar, Fatma Özkan Sipahioğlu, Filiz Karaca Akaslan, Eda Macit Aydın, Evginar Sezer, Derya Özkan
{"title":"Frequency of rebound pain and related factors in a multimodal regimen including systemic dexamethasone and dexmedetomidine.","authors":"Funda Atar, Fatma Özkan Sipahioğlu, Filiz Karaca Akaslan, Eda Macit Aydın, Evginar Sezer, Derya Özkan","doi":"10.1007/s00101-025-01502-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This prospective observational study aimed to explore the frequency and risk factors of rebound pain (RP) in patients treated with multimodal analgesia and intravenous dexamethasone following a peripheral nerve block (PNB).</p><p><strong>Material and methods: </strong>All patients who received preoperative PNB were given a standard multimodal analgesia regimen and intravenous dexamethasone. Motor and sensory block durations, RP severity and frequency were measured for the first 24 h post-PNB using a semistructured questionnaire. The RP was identified as acute postoperative pain within the first 12-24 h after sensory blockade resolution. The severity of RP was determined through the rebound pain score. Contributing risk factors to the development of RP were investigated.</p><p><strong>Results: </strong>After the PNB had worn off RP developed in 27.7%. The following were identified as independent risk factors for RP: patient age, with an adjusted odds ratio (AOR) of 2.3 and a 95% confidence interval (CI) of 1.4-3.9, the use of bupivacaine in combination with lidocaine or prilocaine (AOR: 2.1, 95% CI 1.2-3.8), preoperative pain (AOR: 2.8, 95% CI 1.3-5.6), bone surgery (AOR: 1.8, 95% CI 1.0-3.0) and the duration of the surgery (AOR: 2.8, 95% CI 1.5-5.1).</p><p><strong>Conclusion: </strong>An exact identification of risk factors for RP can aid in creating preventative strategies that target changeable elements. A comprehensive understanding of this occurrence by PNB practitioners can lead to more effective use of PNB, decreased RP instances and improved outcome optimization.</p>","PeriodicalId":72805,"journal":{"name":"Die Anaesthesiologie","volume":" ","pages":"148-155"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Anaesthesiologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00101-025-01502-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This prospective observational study aimed to explore the frequency and risk factors of rebound pain (RP) in patients treated with multimodal analgesia and intravenous dexamethasone following a peripheral nerve block (PNB).

Material and methods: All patients who received preoperative PNB were given a standard multimodal analgesia regimen and intravenous dexamethasone. Motor and sensory block durations, RP severity and frequency were measured for the first 24 h post-PNB using a semistructured questionnaire. The RP was identified as acute postoperative pain within the first 12-24 h after sensory blockade resolution. The severity of RP was determined through the rebound pain score. Contributing risk factors to the development of RP were investigated.

Results: After the PNB had worn off RP developed in 27.7%. The following were identified as independent risk factors for RP: patient age, with an adjusted odds ratio (AOR) of 2.3 and a 95% confidence interval (CI) of 1.4-3.9, the use of bupivacaine in combination with lidocaine or prilocaine (AOR: 2.1, 95% CI 1.2-3.8), preoperative pain (AOR: 2.8, 95% CI 1.3-5.6), bone surgery (AOR: 1.8, 95% CI 1.0-3.0) and the duration of the surgery (AOR: 2.8, 95% CI 1.5-5.1).

Conclusion: An exact identification of risk factors for RP can aid in creating preventative strategies that target changeable elements. A comprehensive understanding of this occurrence by PNB practitioners can lead to more effective use of PNB, decreased RP instances and improved outcome optimization.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
包括全身地塞米松和右美托咪定在内的多模式治疗方案中反跳疼痛的频率及相关因素。
背景:本前瞻性观察研究旨在探讨周围神经阻滞(PNB)后接受多模式镇痛和静脉地塞米松治疗的患者发生反跳痛(RP)的频率和危险因素。材料和方法:所有术前接受PNB的患者均给予标准的多模式镇痛方案和静脉注射地塞米松。运动和感觉阻滞持续时间、RP严重程度和频率在pnb后的前24 h使用半结构化问卷进行测量。RP在感觉封锁解除后的第一个12-24 小时内被确定为急性术后疼痛。通过反跳疼痛评分确定RP的严重程度。研究了RP发生的危险因素。结果:PNB脱落后RP发生率为27.7%。以下被确定为RP的独立危险因素:患者年龄,校正优势比(AOR)为2.3,95%可信区间(CI)为1.4-3.9,布比卡因与利多卡因或普胺卡因联合使用(AOR: 2.1, 95% CI 1.2-3.8),术前疼痛(AOR: 2.8, 95% CI 1.3-5.6),骨手术(AOR: 1.8, 95% CI 1.0-3.0)和手术时间(AOR: 2.8, 95% CI 1.5-5.1)。结论:准确识别RP的危险因素有助于制定针对可变因素的预防策略。PNB从业者对这种情况的全面了解可以更有效地使用PNB,减少RP病例并改善结果优化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Operationalizing the 2025 S3 sepsis update in the ICU: three immediate auditable practice levers for safer, faster care. [Placement of central venous catheters in pediatric anesthesia : Indications, techniques and complications]. [Postdural puncture headache in a 9-year-old female patient: treatment options and trajectory]. Effective treatment of sepsis demands guidelines implementation tailored to available resources. [Putative anaphylactic shock during insertion of a double J ureteral stent].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1